Evidence map›Paper›PMID 35358491›Full record

ArticleThe Lancet. Child & adolescent health2022

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England.

Anna A Mensah, Helen Campbell, Julia Stowe, Giulia Seghezzo, Ruth Simmons, Joanne Lacy, Antoaneta Bukasa, Shennae O'Boyle, Mary E Ramsay, Kevin Brown and 1 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Lancet. Child & adolescent health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study.Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution.

Anna A MensahImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Helen CampbellImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK. Electronic address: helen.campbell@phe.gov.uk.
Julia StoweImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Giulia SeghezzoCOVID-19 EpiCell, UK Health Security Agency, London, UK.
Ruth SimmonsImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Joanne LacyImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Antoaneta BukasaImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Shennae O'BoyleImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Mary E RamsayImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Kevin BrownImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Shamez N LadhaniImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
UK Health Security Agency

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReinfection after primary SARS-CoV-2 infection is uncommon in adults, but little is known about the risks, characteristics, severity, or outcomes of reinfection in children. We aimed to assess the risk of SARS-CoV-2 reinfection in children and compare this with the risk in adults, by analysis of national testing data for England.

methodsIn our prospective, national surveillance study to assess reinfection of SARS-CoV-2 in children in England, we used national SARS-CoV-2 testing data to estimate the risk of reinfection at least 90 days after primary infection from Jan 27, 2020, to July, 31, 2021, which encompassed the alpha (B.1.1.7) and delta (B.1.617.2) variant waves in England. Data from children up to age 16 years who met the criteria for reinfection were included. Disease severity was assessed by linking reinfection cases to national hospital admission data, intensive care admission, and death registration datasets.

findingsReinfection rates closely followed community infection rates, with a small peak during the alpha wave and a larger peak during the delta wave. In children aged 16 years and younger, 688 418 primary infections and 2343 reinfections were identified. The overall reinfection rate was 66·88 per 100 000 population, which was higher in adults (72·53 per 100 000) than children (21·53 per 100 000). The reinfection rate after primary infection was 0·68% overall, 0·73% in adults compared with 0·18% in children age younger than 5 years, 0·24% in those aged 5-11 years, and 0·49% in those aged 12-16 years. Of the 109 children admitted to hospital with reinfection, 78 (72%) had comorbidities. Hospital admission rates were similar for the first (64 [2·7%] of 2343) and second episode (57 [2·4%] of 2343) and intensive care admissions were rare (seven children for the first episode and four for reinfections). There were 44 deaths within 28 days after primary infection (0·01%) and none after reinfection.

interpretationThe risk of SARS-CoV-2 reinfection is strongly related to exposure due to community infection rates, especially during the delta variant wave. Children had a lower risk of reinfection than did adults, but reinfections were not associated with more severe disease or fatal outcomes.

fundingUK Health Security Agency.

Indexed as

COVID-19SARS-CoV-2AdultChildCOVID-19 TestingEnglandHumansProspective StudiesReinfection

Identifiers

PMID35358491
PMCPMC8959472
OpenAlexW4220685064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.